Verona Pharma’s (VRP) “Buy” Rating Reiterated at Shore Capital

Shore Capital reiterated their buy rating on shares of Verona Pharma (LON:VRP) in a report issued on Tuesday morning.

Separately, Jefferies Financial Group reissued a buy rating on shares of Verona Pharma in a report on Friday, January 4th.

Shares of LON VRP opened at GBX 50 ($0.65) on Tuesday. Verona Pharma has a 52-week low of GBX 100 ($1.31) and a 52-week high of GBX 189 ($2.47).

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Featured Article: Cost of Equity

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with's FREE daily email newsletter.

Leave a Reply